Eli Lilly's 2022 performance was characterized by several key milestones:
In a year marked by significant shifts in the pharmaceutical landscape, reaffirmed its Neutral rating on Eli Lilly and Company (LLY) during 2022. While the drugmaker demonstrated robust growth potential driven by its late-stage pipeline, analysts at the investment bank remained cautious regarding the stock’s valuation and broader macroeconomic headwinds. The 2022 Backdrop: Growth vs. Valuation
Investors closely watched the progress of donanemab , Lilly’s experimental Alzheimer’s drug, which faced a complex regulatory environment following the controversial rollout of rival treatments. Eli Lilly's 2022 performance was characterized by several
As a "defensive" stock, Eli Lilly benefited from investor rotation away from high-growth tech and into stable healthcare companies during the inflationary periods of 2022. Why "Neutral"?
A opinion from Goldman Sachs typically indicates that the firm expects the stock’s performance to be generally in line with the average return of the stocks in the analyst's coverage universe. For Eli Lilly, this rating reflected a balance between: A opinion from Goldman Sachs typically indicates that
Concerns that the stock had become a "crowded trade," making it vulnerable to any minor earnings misses or clinical setbacks. Market Impact
The maintenance of the Neutral stance did little to dampen investor enthusiasm in the long term. While the rating suggested a lack of immediate "buy" urgency from the bank's perspective, Eli Lilly finished 2022 as one of the best-performing large-cap pharmaceutical companies, setting the stage for its continued ascent in the years that followed. Lilly’s experimental Alzheimer’s drug
The FDA approval of tirzepatide for type 2 diabetes in May 2022 served as a major catalyst for the stock.